| 1. |
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 2016, 87(4): 419-425.
|
| 2. |
Alhaidar MK, Abumurad S, Soliven B, et al. Current treatment of myasthenia gravis. J Clin Med, 2022, 11(6): 1597.
|
| 3. |
常婷, 李柱一. 中國重癥肌無力研究進展近十年回顧與展望. 中國神經免疫學和神經病學雜志, 2022, 29(5): 349-355.
|
| 4. |
Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol, 2020, 11: 538.
|
| 5. |
譚群友, 陶紹霖, 劉寶東, 等. 重癥肌無力外科治療中國臨床專家共識. 中國胸心血管外科臨床雜志, 2022, 29(5): 529-541.
|
| 6. |
Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med, 2016, 375(6): 511-522.
|
| 7. |
Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol, 2019, 18(3): 259-268.
|
| 8. |
秦雨涵, 侯宏衛, 胡清源. α7煙堿型乙酰膽堿受體在膽堿能抗炎通路中的作用機制及應用現狀. 中國生物化學與分子生物學報, 2022, 38(10): 1304-1310.
|
| 9. |
黃朋偉, 龐天寶, 陳嘉捷, 等. α7煙堿樣乙酰膽堿受體在重癥肌無力患者外周血單個核細胞中的表達及對T細胞活化的影響. 鄭州大學學報(醫學版), 2020, 55(4): 463-467.
|
| 10. |
中國免疫學會神經免疫分會. 中國重癥肌無力診斷和治療指南 (2020版). 中國神經免疫學和神經病學雜志, 2021, 28(1): 1-12.
|
| 11. |
Gilhus NE, Verschuuren JJ. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol, 2015, 14(10): 1023-1036.
|
| 12. |
Zhang X, Liu S, Chang T, et al. Intrathymic Tfh/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: Central role in triggering MG occurrence. Mol Neurobiol, 2016, 53(1): 120-131.
|
| 13. |
Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest, 2007, 117(2): 289-296.
|
| 14. |
周國勇, 胡森. 煙堿型乙酰膽堿受體與臨床疾病. 基礎醫學與臨床, 2007, 27(5): 584-587.
|
| 15. |
Hoskin JL, Al-Hasan Y, Sabbagh MN. Nicotinic acetylcholine receptor agonists for the treatment of Alzheimer's Dementia: An update. Nicotine Tob Res, 2019, 21(3): 370-376.
|
| 16. |
Klimova EM, Drozdova LA, Lavinskaya EV, et al. Genomic and epigenomic predictors for various clinical phenotypes of myasthenia gravis. Wiad Lek. 2021, 74(3): 475-480.
|
| 17. |
Moiola L, Galbiati F, Martino G, et al. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol, 1998, 28(8): 2487-2497.
|
| 18. |
Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation, 2017, 14(1): 117.
|
| 19. |
Ahlberg R, Yi Q, Pirskanen R, et al. Treatment of myasthenia gravis with anti-CD4 antibody: Improvement correlates to decreased T-cell autoreactivity. Neurology, 1994, 44(9): 1732-1737.
|
| 20. |
Conti-Fine BM, Milani M, Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci, 2008, 1132: 193-209.
|